Drugs / IC41
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00601770 | Feb 2006 → Jul 2008 | chronic hepatitis C virus infection | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00602784 | Nov 2002 → May 2004 | chronic hepatitis C virus infection | Valneva Austria GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IC41 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00602784 ↗ |
| Modality | Vaccine | “IC41, a Therapeutic HCV Vaccine” NCT00601770 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT00602784 ↗ |